Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?
Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?
复制标题
DOI：
10.1007/s11912-007-0031-2
复制
发表时间：
2007-07-01
影响因子：
4.7
通讯作者：
Brahmer, Julie
中科院分区：
文献类型：
--
作者：
Juergens, Rosalyn;Brahmer, Julie
表皮生长因子受体信号级联的异常对于几种实体瘤来说是常见的。美国食品和药物管理局已批准针对该途径的化合物用于治疗肺癌、头颈癌、胰腺癌和结直肠癌。不幸的是，只有少数接受此类药物治疗的患者会出现反应或生存率得到改善。本文回顾了利用肿瘤对表皮生长因子受体级联的依赖性的药物的数据，并描述了如何辨别接受这些药物的适当患者群体的知识。
Aberrations in the signaling cascade of the epidermal growth factor receptor are common to several solid tumors. Compounds aimed at targeting this pathway have been approved for use by the US Food and Drug Administration for lung, head and neck, pancreas, and colorectal carcinomas. Unfortunately, only the minority of patients treated with this class of agents will have responses or improvements in survival. This article reviews the data on agents that exploit tumor dependency on epidermal growth factor receptor cascade and describes the knowledge on how to discern the appropriate patient population for receiving these agents.